Page last updated: 2024-11-06

1-octacosanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-Octacosanol, also known as octacosanol or n-octacosanol, is a long-chain fatty alcohol naturally occurring in plants. It is a white, waxy solid at room temperature. Research suggests potential benefits for human health, including improved athletic performance, enhanced immune function, and reduced inflammation. However, more research is needed to confirm these effects and determine optimal dosages. Its synthesis is often achieved through extraction from natural sources or through chemical processes involving fatty acids. 1-Octacosanol is studied for its potential applications in various fields, including food additives, cosmetics, and pharmaceuticals.'

1-octacosanol: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

octacosan-1-ol : An ultra-long-chain primary fatty alcohol that is octacosane in which a hydrogen attached to one of the terminal carbons is replaced by a hydroxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID68406
CHEMBL ID1951714
CHEBI ID28243
SCHEMBL ID16043
MeSH IDM0129543

Synonyms (56)

Synonym
AKOS015839868
CHEBI:28243 ,
octacosanol-1
nsc-57768
nsc57768
n-octacosanol
cluytyl alcohol
nsc-10770
nsc10770
octacosyl alcohol
montanyl alcohol
octacosyl
einecs 209-181-2
nsc 10770
1-octacosanol
octacosanol
octacosan-1-ol
557-61-9
C08387
1-octacosanol, >=99% (gc)
LMFA05000003
O0199
81i2215ovk ,
unii-81i2215ovk
A830795
octanosol
CHEMBL1951714
FT-0603471
octacosanol [who-dd]
octacosanol [mi]
octacosanol (constituent of saw palmetto) [dsc]
octacosanol [mart.]
S5161
SCHEMBL16043
Q-100644
mfcd00044770
DTXSID1025803 ,
o8n ,
SR-01000944875-1
sr-01000944875
68580-63-2
DB11220
Q3631024
F17671
octacosanol,(s)
AS-14389
CS-W011677
HY-N6811
CCG-268780
NCGC00274075-01
octacosanol,95%
DTXSID901019021 ,
octacosanol (mart.)
octacosanol (constituent of saw palmetto)
dtxcid305803
SY052221

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" A pronounced increase in release/diffusion rate and bioavailability was observed for the nanocrystals of the modified octacosanol."( Octacosanol educes physico-chemical attributes, release and bioavailability as modified nanocrystals.
Ghosh, M; Sen Gupta, S, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
"The present study demonstrates that octacosanoic acid is formed after incubation of fibroblast cultures with (3)H-octacosanol and after oral dosing with policosanol to rats."( In vitro and in vivo study of octacosanol metabolism.
Fernández, I; González, L; González, RM; Marrero, D; Más, R; Menéndez, R,
)
0.13
"We planned to carry out a pilot study to evaluate the efficacy and safety as an antihypercholesterolemic agent of a brand dietary supplement made of Monascus purpureus titrated extract, octacosanols and niacin on 111 Caucasian patients with low cardiovascular disease risk (<20% by Framingham algorithms), comparing them with the antihypercholesterolemic effect of a low dosage of Pravastatin on 20 subjects with similar risk profile."( Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study.
Brancaleoni, M; Cicero, AF; Donati, F; Laghi, L; Mino, M, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
fatty alcohol 28:0Any fatty alcohol containing 28 carbons.
ultra-long-chain primary fatty alcoholAny primary fatty alcohol with a chain length greater than C27.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID647809Antifilarial activity against adult Brugia malayi assessed as inhibition of motility at 15.6 ug/ml incubated for 48 hrs followed by washout measured after 1 hr in the absence of drug by microscopic analysis2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647804Antifilarial activity against microfilariae Brugia malayi after 48 hrs by MTT assay2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647814Antifilarial activity against microfilariae Brugia malayi assessed as inhibition of motility at 15.6 ug/ml incubated for 48 hrs followed by washout measured after 1 hr in the absence of drug by microscopic analysis2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647805Cytotoxicity against african green monkey Vero cells after 72 hrs by resazurin dye-based fluorimetric analysis2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647826Antifilarial activity against adult Brugia malayi infected in jird assessed as sterilized female worm at 50 mg/kg, ip administered for 5 consecutive days measured on day 512012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647807Selectivity ratio of CC50 for african green monkey Vero cells to IC50 for microfilariae Brugia malayi2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647820Antifilarial activity against adult Brugia malayi at 7.8 ug/ml by MTT assay relative to control2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647808Antifilarial activity against adult Brugia malayi assessed as inhibition of motility at 31.25 ug/ml incubated for 48 hrs followed by washout measured after 1 hr in the absence of drug by microscopic analysis2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647803Antifilarial activity against adult Brugia malayi after 48 hrs by MTT assay2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647818Antifilarial activity against adult Brugia malayi at 31.25 ug/ml by MTT assay relative to control2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647815Antifilarial activity against microfilariae Brugia malayi assessed as inhibition of motility at 7.8 ug/ml incubated for 48 hrs followed by washout measured after 1 hr in the absence of drug by microscopic analysis2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647813Antifilarial activity against microfilariae Brugia malayi assessed as inhibition of motility at 31.25 ug/ml incubated for 48 hrs followed by washout measured after 1 hr in the absence of drug by microscopic analysis2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647824Antifilarial activity against adult Brugia malayi infected in jird assessed as worm mortality at 50 mg/kg, ip administered for 5 consecutive days measured on day 512012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647819Antifilarial activity against adult Brugia malayi at 15.6 ug/ml by MTT assay relative to control2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
AID647810Antifilarial activity against adult Brugia malayi assessed as inhibition of motility at 7.8 ug/ml incubated for 48 hrs followed by washout measured after 1 hr in the absence of drug by microscopic analysis2012European journal of medicinal chemistry, Apr, Volume: 50Galactolipids from Bauhinia racemosa as a new class of antifilarial agents against human lymphatic filarial parasite, Brugia malayi.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (9.68)18.7374
1990's6 (9.68)18.2507
2000's21 (33.87)29.6817
2010's21 (33.87)24.3611
2020's8 (12.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.36 (24.57)
Research Supply Index4.29 (2.92)
Research Growth Index4.86 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (12.50%)5.53%
Reviews3 (4.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (82.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]